Major Tranquilizers Market
Segments - by Types (First Generation, Second Generation, and Third Generation), Applications (Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028.
The global major tranquilizer market size was valued at USD 2.0 billion in 2020 and is projected to reach USD 2.4 billion by 2028 at a CAGR of 3.4% during the forecast period. The growth of the market is attributed to its drivers such as rising health issues in people.
Tranquilizer reduces mental tension, relieve anxiety, and result in outlook without producing any marked degree of hypnosis or sedation. Tranquilizers play a vital role in psychological disorder treatments. During these postmodern eras mental illness is common in many people because of the work pressure, tension, and anxiety. The conventional antipsychotic was first developed in 1950s and was widely prescribed for the treatment of severe mental disorders. Thorazine (chlorpromazine) and Haldol (haloperidol) were the most commonly used typical antipsychotics. Atypical antipsychotics were approved in the 1990s for treating various psychiatric disorders. These drugs were effective as compared to typical antipsychotics. In the fourth coming years more effective drugs may be launched in the market. The drug needs to be given under the supervision of expert, the patient can even loose, he’s or her lives if not given in correct measure or amount.
Market Trends, Drivers, Restraints, and Opportunities
- Increase in mental illness is projected to drive the the market.
- Increasing geriatric population may increase the number of patients suffering from psychiatric disorders; this in turn is estimated to boost the market.
- R&D investment and technological advancement for new products innovations is anticipated to create lucrative opportunities for the market players.
Scope of the Report
The report on the global tranquilizer market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | Major Tranquilizers Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
| Base Year | 2020 |
| Historic Data | 2018–2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Types (First Generation, Second Generation, and Third Generation) and Applications (Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, and Others) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
| Key Players Covered in the Report | Johnson & Johnson, Pfizer, Eli Lilly, Bristol-Myers Squibb, AstraZeneca, GSK, and Allergan |
Market Segment Insights:
The first generation segment is estimated to expand at a rapid pace
Based on type, the global major tranquilizer market is segmented as first, second, and third generation. The first generation segment is projected to expand at a CAGR of 4% during the forecast period. Market growth is attributed to rising depression due to changing lifestyle and increasing number of mental hospitals. First generation drugs are used primarily for the treatment of schizophrenia and related psychotic disorder. The exact mechanism of action of antipsychotic drugs is unknown.
Second-generation drugs generally have lower risk of extrapyramidal side effects and tardive dyskinesia compared with first-generation. First- and second-generation antipsychotic drugs are more comparable in their clinical efficacy, with the exception of clozapine.
The bipolar disorder segment is estimated to expand at a CAGR of 5.2% during the forecast period
On the basis of applications, the global major tranquilizer market is fragmented into schizophrenia, bipolar disorder, unipolar depression, dementia, and others. The bipolar segment is anticipated to hold a major market share. Growth of the market is estimated to rising prevalence of mental illness and rising product launches. This kind of treatment should be done under supervision of expert and in proper measure. Medicine gives temporary relief to the medical condition.
The market in North America is projected to hold a major market share
In terms of regions, the global major tranquilizer market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in North America is subjected to hold major share in the global market during the forecast period. According to food and drug administration (FDA), over 60 million people receive prescriptions for tranquilizers every year. One in five adults is living with some or the other mental illness.
Countries in Asia Pacific such as China, Japan, and Australia exhibit significant growth prospects in terms of rapid acceptance of novel molecules as well as the extensive use of generics. This region has a large number of patients suffering from psychological distress, cancer, AIDS, and other chronic disorders which is estimated to propel the market.
Segments
Segments Covered in the ReportThe global major tranquilizers market is segmented on the basis of
Types
- First Generation
- Second Generation
- Third Generation
- Schizophrenia
- Bipolar Disorder
- Unipolar Depression
- Dementia
- Others
- Asia Pacific
- North America
- Latin America
- Europe
- Johnson & Johnson
- Pfizer
- Eli Lilly
- Bristol-Myers Squibb
- AstraZeneca
- GSK
- Allergan
Competitive Landscape
The global major tranquilizers market is highly competitive and major market players include Johnson & Johnson, Pfizer, Eli Lilly, Bristol-Myers Squibb, AstraZeneca, GSK, and Allergan. Rise in psychological disorders is expected to drive the tranquilizer drugs market. Currently the market is facing the production problem because on partial lock down caused due to Covid - 19 pandemic as operation cannot be done in full capacity.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Major Tranquilizers Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Major Tranquilizers Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Major Tranquilizers Market - Supply Chain
4.5. Global Major Tranquilizers Market Forecast
4.5.1. Major Tranquilizers Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Major Tranquilizers Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Major Tranquilizers Market Absolute $ Opportunity
5. Global Major Tranquilizers Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Major Tranquilizers Market Size and Volume Forecast by Types
5.3.1. First Generation
5.3.2. Second Generation
5.3.3. Third Generation
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Major Tranquilizers Market Analysis and Forecast by End Users
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by End Users
6.2.2. Y-o-Y Growth Projections by End Users
6.3. Major Tranquilizers Market Size and Volume Forecast by End Users
6.3.1. Schizophrenia
6.3.2. Bipolar Disorder
6.3.3. Unipolar Depression
6.3.4. Dementia
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by End Users
6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Major Tranquilizers Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Major Tranquilizers Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Major Tranquilizers Demand Share Forecast, 2019-2026
8. North America Major Tranquilizers Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Major Tranquilizers Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Major Tranquilizers Market Size and Volume Forecast by Types
8.4.1. First Generation
8.4.2. Second Generation
8.4.3. Third Generation
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. North America Major Tranquilizers Market Size and Volume Forecast by End Users
8.7.1. Schizophrenia
8.7.2. Bipolar Disorder
8.7.3. Unipolar Depression
8.7.4. Dementia
8.7.5. Others
8.8. Basis Point Share (BPS) Analysis by End Users
8.9. Y-o-Y Growth Projections by End Users
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Major Tranquilizers Demand Share Forecast, 2019-2026
9. Latin America Major Tranquilizers Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Major Tranquilizers Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Major Tranquilizers Market Size and Volume Forecast by Types
9.4.1. First Generation
9.4.2. Second Generation
9.4.3. Third Generation
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Latin America Major Tranquilizers Market Size and Volume Forecast by End Users
9.7.1. Schizophrenia
9.7.2. Bipolar Disorder
9.7.3. Unipolar Depression
9.7.4. Dementia
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by End Users
9.9. Y-o-Y Growth Projections by End Users
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Major Tranquilizers Demand Share Forecast, 2019-2026
10. Europe Major Tranquilizers Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Major Tranquilizers Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Major Tranquilizers Market Size and Volume Forecast by Types
10.4.1. First Generation
10.4.2. Second Generation
10.4.3. Third Generation
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Europe Major Tranquilizers Market Size and Volume Forecast by End Users
10.7.1. Schizophrenia
10.7.2. Bipolar Disorder
10.7.3. Unipolar Depression
10.7.4. Dementia
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by End Users
10.9. Y-o-Y Growth Projections by End Users
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Major Tranquilizers Demand Share Forecast, 2019-2026
11. Asia Pacific Major Tranquilizers Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Major Tranquilizers Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Major Tranquilizers Market Size and Volume Forecast by Types
11.4.1. First Generation
11.4.2. Second Generation
11.4.3. Third Generation
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Asia Pacific Major Tranquilizers Market Size and Volume Forecast by End Users
11.7.1. Schizophrenia
11.7.2. Bipolar Disorder
11.7.3. Unipolar Depression
11.7.4. Dementia
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by End Users
11.9. Y-o-Y Growth Projections by End Users
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Major Tranquilizers Demand Share Forecast, 2019-2026
12. Middle East & Africa Major Tranquilizers Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Major Tranquilizers Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Major Tranquilizers Market Size and Volume Forecast by Types
12.4.1. First Generation
12.4.2. Second Generation
12.4.3. Third Generation
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Middle East & Africa Major Tranquilizers Market Size and Volume Forecast by End Users
12.7.1. Schizophrenia
12.7.2. Bipolar Disorder
12.7.3. Unipolar Depression
12.7.4. Dementia
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by End Users
12.9. Y-o-Y Growth Projections by End Users
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Major Tranquilizers Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Major Tranquilizers Market: Market Share Analysis
13.2. Major Tranquilizers Distributors and Customers
13.3. Major Tranquilizers Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. Johnson & Johnson
13.4.2. Pfizer
13.4.3. Eli Lilly
13.4.4. Bristol-Myers Squibb
13.4.5. AstraZeneca
13.4.6. GSK
13.4.7. Allergan
2. Assumptions and Acronyms Used
3. Research Methodology
4. Major Tranquilizers Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Major Tranquilizers Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Major Tranquilizers Market - Supply Chain
4.5. Global Major Tranquilizers Market Forecast
4.5.1. Major Tranquilizers Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Major Tranquilizers Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Major Tranquilizers Market Absolute $ Opportunity
5. Global Major Tranquilizers Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Major Tranquilizers Market Size and Volume Forecast by Types
5.3.1. First Generation
5.3.2. Second Generation
5.3.3. Third Generation
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Major Tranquilizers Market Analysis and Forecast by End Users
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by End Users
6.2.2. Y-o-Y Growth Projections by End Users
6.3. Major Tranquilizers Market Size and Volume Forecast by End Users
6.3.1. Schizophrenia
6.3.2. Bipolar Disorder
6.3.3. Unipolar Depression
6.3.4. Dementia
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by End Users
6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Major Tranquilizers Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Major Tranquilizers Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Major Tranquilizers Demand Share Forecast, 2019-2026
8. North America Major Tranquilizers Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Major Tranquilizers Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Major Tranquilizers Market Size and Volume Forecast by Types
8.4.1. First Generation
8.4.2. Second Generation
8.4.3. Third Generation
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. North America Major Tranquilizers Market Size and Volume Forecast by End Users
8.7.1. Schizophrenia
8.7.2. Bipolar Disorder
8.7.3. Unipolar Depression
8.7.4. Dementia
8.7.5. Others
8.8. Basis Point Share (BPS) Analysis by End Users
8.9. Y-o-Y Growth Projections by End Users
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Major Tranquilizers Demand Share Forecast, 2019-2026
9. Latin America Major Tranquilizers Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Major Tranquilizers Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Major Tranquilizers Market Size and Volume Forecast by Types
9.4.1. First Generation
9.4.2. Second Generation
9.4.3. Third Generation
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Latin America Major Tranquilizers Market Size and Volume Forecast by End Users
9.7.1. Schizophrenia
9.7.2. Bipolar Disorder
9.7.3. Unipolar Depression
9.7.4. Dementia
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by End Users
9.9. Y-o-Y Growth Projections by End Users
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Major Tranquilizers Demand Share Forecast, 2019-2026
10. Europe Major Tranquilizers Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Major Tranquilizers Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Major Tranquilizers Market Size and Volume Forecast by Types
10.4.1. First Generation
10.4.2. Second Generation
10.4.3. Third Generation
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Europe Major Tranquilizers Market Size and Volume Forecast by End Users
10.7.1. Schizophrenia
10.7.2. Bipolar Disorder
10.7.3. Unipolar Depression
10.7.4. Dementia
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by End Users
10.9. Y-o-Y Growth Projections by End Users
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Major Tranquilizers Demand Share Forecast, 2019-2026
11. Asia Pacific Major Tranquilizers Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Major Tranquilizers Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Major Tranquilizers Market Size and Volume Forecast by Types
11.4.1. First Generation
11.4.2. Second Generation
11.4.3. Third Generation
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Asia Pacific Major Tranquilizers Market Size and Volume Forecast by End Users
11.7.1. Schizophrenia
11.7.2. Bipolar Disorder
11.7.3. Unipolar Depression
11.7.4. Dementia
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by End Users
11.9. Y-o-Y Growth Projections by End Users
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Major Tranquilizers Demand Share Forecast, 2019-2026
12. Middle East & Africa Major Tranquilizers Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Major Tranquilizers Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Major Tranquilizers Market Size and Volume Forecast by Types
12.4.1. First Generation
12.4.2. Second Generation
12.4.3. Third Generation
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Middle East & Africa Major Tranquilizers Market Size and Volume Forecast by End Users
12.7.1. Schizophrenia
12.7.2. Bipolar Disorder
12.7.3. Unipolar Depression
12.7.4. Dementia
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by End Users
12.9. Y-o-Y Growth Projections by End Users
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Major Tranquilizers Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Major Tranquilizers Market: Market Share Analysis
13.2. Major Tranquilizers Distributors and Customers
13.3. Major Tranquilizers Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. Johnson & Johnson
13.4.2. Pfizer
13.4.3. Eli Lilly
13.4.4. Bristol-Myers Squibb
13.4.5. AstraZeneca
13.4.6. GSK
13.4.7. Allergan
Our Clients
Related Reports
Some other reports from this category!
